Niflumic acid

Research use only, not for human use.

Niflumic acid, a Ca2+-activated Cl- channel blocker, is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.

Niflumic acid, a Ca2+-activated Cl- channel blocker, is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.

Cell Viability Assay Cell Line: A549, H460, and H1299 cells Concentration:0 μM, 100 μM,200 μM, 300 μM Incubation Time:48 h Result:Showed a marked synergistic decrease in cell viability with Ciglitazone.Apoptosis Analysis Cell Line: A549, H460, and H1299 cells Concentration:100 μM, 200 μM Incubation Time:48 h Result:Showed a marked synergistic increase apoptosis with Ciglitazone.Cell Viability Assay Cell Line: A549, H460, and H1299 cells Concentration:100 μM Incubation Time:30 h Result:Showed a marked synergistic increase of proteins level of caspase-8, Bid, and Bax with Ciglitazone.

Animal Model:Pig with asthma Dosage:30 mg/kg Administration:InhalationResult: Showed significantly inhibiting the decrease in mucus area.

Actol | Donalgin | Nifluril | UP83

Chromatin/Epigenetic

COX

COX| Monocarboxylate transporter| Chloride channel protein ClC-Ka| PLA2| UGT

Inflammation/Immunology

——

4394-00-7

282.22

C13H9F3N2O2

>98% (HPLC)

DMSO: 56 mg/mL (198.42 mM)

O=C(C1=CC=CN=C1NC2=CC=CC(C(F)(F)F)=C2)O

2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylic acid

(-20℃)

With Ice Pack

≥ 2 years